Summary:
Open-label Study of Safety and Tolerability of Chronic
Intermittent Usage for 24 or 52 Weeks of Intranasal
Dihydroergotamine Mesylate (DHE) Administered using
the I123 Precision Olfactory Delivery (POD®) Device
[INP104, POD-DHE] in Patients with Migraine Headache
Qualified Participants Must:
• Adult males and females, 18 to 65 years of age
•
Must have documented diagnosis of migraine
Qualified Participants May Receive:
Compensation for time and travel